Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
NNX 0.035 +0.0% ABX 51.92 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.70 +9.1% TUNG 1.74 +3.0% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.49 +0.9% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.305 −4.7% DEX 0.390 +1.3% WMS 0.040 +0.0% NNX 0.035 +0.0% ABX 51.92 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.70 +9.1% TUNG 1.74 +3.0% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.49 +0.9% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.305 −4.7% DEX 0.390 +1.3% WMS 0.040 +0.0%
Other Routine +

AN INDEPENDENT EVALUATION CONFIRMS THE CLINICAL AND ORGANIZATIONAL BENEFITS OF THE MEDHERIZE PLATFORM IN BREAST ONCOLOGY

Clinical validation of Medherize confirms value prop, but tiny revenue and depleted cash demand urgent capital raise.

By The Northwire Desk — AI Analysis Jun 18, 2026 · 13:15 KDA · 0.075 KDA Group Inc.
Executive Summary
  • KDA Group announced the results of an independent evaluation of its Medherize digital platform for breast oncology patients.
  • The platform achieved a 97% patient adoption rate, 93% therapeutic adherence, and a 52% reduction in required pharmacist full-time equivalents.
  • Medical consultations and administrative interventions decreased by 80%, with an 86% patient satisfaction rate.
  • The evaluating clinical team recommends making Medherize a permanent monitoring tool.
  • KDA plans to expand the platform to other oral anticancer medications to address labor shortages and an aging patient population.
  • This follows a series of prior announcements detailing the deployment of Medherize at Quebec hospitals, community pharmacies, and the planned opening of a U.S. subsidiary.
Material Impact
  • The news provides clinical and operational validation of Medherize, addressing a critical hurdle for digital health platforms: proving real-world efficacy to providers and payers.
  • However, the impact on the stock is incremental. The platform was already deployed at CHU de Québec and community pharmacies in late 2025. This evaluation is a logical follow-up confirming the partnership's success rather than a new commercial contract or revenue inflection.
  • No financial terms, subscription volumes, or revenue recognition metrics are disclosed. The market has already priced in the deployment phase; this is a quality-of-earnings/commercial validation step that does not materially alter the financial trajectory in the near term.
KDA · Price
Company Overview
  • KDA Group Inc. operates in the healthcare technology sector, focusing on digital health solutions for oncology and specialty medications.
  • Its flagship product, Medherize, is a SaaS platform designed to improve therapeutic adherence, monitor adverse effects, and streamline coordination between oncologists, pharmacists, and patients.
  • The company has been aggressively expanding its commercial footprint, securing partnerships with major Quebec hospital networks and community pharmacies, and preparing for U.S. market entry.
  • The business model relies on SaaS subscriptions and potential partnerships with pharmaceutical companies and pharmacy chains.
Read the original news release →

More from KDA Group Inc.

May 29, 2026 · 18:00

KDA Group Settles Debt with Equity Amidst Share Price Collapse

Financings May 05, 2026 · 13:30

Governance Cleanup Amidst Valuation Trough

Regulatory Dec 24, 2025 · 11:00

UPDATE OF THE TRANSACTION ANNOUNCED ON NOVEMBER 25, 2025, FOR THE ACQUISITION OF THE MINORITY INTEREST IN THE SUBSIDIARY GROUPE TECHNOLOGIQUE KDA INC.

M&A / Property Dec 03, 2025 · 10:30

KDA GROUP ANNOUNCES PARTNERSHIP AGREEMENT WITH CHU DE QUEBEC-UNIVERSITE LAVAL FOR THE DEPLOYMENT OF MEDHERIZE

M&A / Property Dec 01, 2025 · 13:45

KDA GROUP DEPLOYS MEDHERIZE ACROSS COMMUNITY PHARMACIES: A MAJOR STEP FORWARD IN THE MANAGEMENT OF ORAL ANTICANCER THERAPIES

Production / Operations Nov 25, 2025 · 15:00

KDA GROUP ANNOUNCES AGREEMENT TO ACQUIRE MINORITY INTEREST IN ITS SUBSIDIARY GROUPE TECHNOLOGIQUE KDA INC.

M&A / Property